CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the other hand, Berubicin, “a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain, is currently entering a potentially pivotal Phase 2 study for GBM.”
To view the full article, visit https://ibn.fm/qksQU
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.